Tekla Life Sciences Stock Fundamentals
| HQL Stock | USD 13.83 0.47 3.29% |
Tekla Life Sciences fundamentals help investors to digest information that contributes to Tekla Life's financial success or failures. It also enables traders to predict the movement of Tekla Stock. The fundamental analysis module provides a way to measure Tekla Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tekla Life stock.
Tekla |
Tekla Life Sciences Company Profit Margin Analysis
Tekla Life's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Tekla Life Profit Margin | 1.56 % |
Most of Tekla Life's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tekla Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Tekla Life Sciences has a Profit Margin of 1.5645%. This is 86.58% lower than that of the Capital Markets sector and 90.03% lower than that of the Financials industry. The profit margin for all United States stocks is notably lower than that of the firm.
Tekla Life Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tekla Life's current stock value. Our valuation model uses many indicators to compare Tekla Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tekla Life competition to find correlations between indicators driving Tekla Life's intrinsic value. More Info.Tekla Life Sciences is rated # 2 in return on equity category among its peers. It is rated # 3 in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Tekla Life by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Tekla Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tekla Life's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tekla Life could also be used in its relative valuation, which is a method of valuing Tekla Life by comparing valuation metrics of similar companies.Tekla Life is currently under evaluation in profit margin category among its peers.
Tekla Fundamentals
| Return On Equity | 0.0128 | |||
| Return On Asset | -0.0032 | |||
| Profit Margin | 1.56 % | |||
| Operating Margin | (0.32) % | |||
| Current Valuation | 370.8 M | |||
| Shares Outstanding | 27.35 M | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 35.34 % | |||
| Number Of Shares Shorted | 63.15 K | |||
| Price To Earning | 2.84 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 111.34 X | |||
| Revenue | 23.52 M | |||
| Gross Profit | 3.02 M | |||
| EBITDA | 22.35 M | |||
| Net Income | 22.35 M | |||
| Cash And Equivalents | 292.4 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 666.96 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 1.34 X | |||
| Book Value Per Share | 16.13 X | |||
| Cash Flow From Operations | (12.8 M) | |||
| Short Ratio | 0.93 X | |||
| Earnings Per Share | 1.34 X | |||
| Number Of Employees | 11 | |||
| Beta | 0.71 | |||
| Market Capitalization | 391.11 M | |||
| Total Asset | 402.6 M | |||
| Retained Earnings | (1.48 M) | |||
| Annual Yield | 0.14 % | |||
| Five Year Return | 8.83 % | |||
| Net Asset | 402.6 M | |||
| Last Dividend Paid | 1.3 |
About Tekla Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tekla Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tekla Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tekla Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Tekla Life operates under Asset Management classification in the United States and is traded on New York Stock Exchange.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Tekla Life Piotroski F Score and Tekla Life Altman Z Score analysis. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.